Consensus Nuvectis Pharma, Inc.

Equities

NVCT

US67080T1088

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
6.15 ^USD	-5.82%		-3.91%	-26.26%

05-07	Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	CI

Evolution of the average Target Price on Nuvectis Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d68a2408086267924139498c.d1Rkpt6GPwPW3wM9IANnyC_siUyRuULWAskPjQ3UVRY.QxIn-ZXRYGC9qHRyEmgymliW7znp0S_gMPA90m-cHEUhYjf_ifZUQa_mcA~05b14e228d3cfe88eccf1d53bd4dabac

Analyst Recommendations on Nuvectis Pharma, Inc.

Ladenburg Thalmann Initiates Nuvectis Pharma at Buy with $21 Price Target	22-07-13	MT
HC Wainwright Initiates Nuvectis Pharma at Buy With $14 Price Target	22-03-02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.15 USD

Average target price

22 USD

Spread / Average Target

+257.72%

High Price Target

25 USD

Spread / Highest target

+306.50%

Low Price Target

20 USD

Spread / Lowest Target

+225.20%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Nuvectis Pharma, Inc.

Ladenburg Thalmann
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar